The total return over the past 12 months is +69.07% vs. +16.94% for the S&P 500. So far it's up +62.25% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +69.07% | +74.09% | +30.72% | +17.12% | +27.06% | +11.12% |
| Total Return CAGR | +69.07% | +74.09% | +30.72% | +17.12% | +27.06% | +13.19% |
| Revenue CAGR | +54.89% | +22.87% | +2.92% | +12.68% | +18.39% | +2.12% |
| Net Income CAGR | N/A | +93.62% | +32.73% | (0.45%) | +39.27% | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | +229.23% | +10.34% | (0.49%) | +20.66% | N/A | N/A |
| Operating Cash Flow CAGR | +138.13% | +6.88% | +24.28% | +10.71% | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Ligand Pharmaceuticals Incorporated (LGND)
| Year | Start price | End price | LGND Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $189.07 | $306.77 | +62.25% | +14.51% | +47.74% |
| 2025 | $107.15 | $189.07 | +76.45% | +17.72% | +58.73% |
| 2024 | $71.42 | $107.15 | +50.03% | +24.89% | +25.14% |
| 2023 | $66.80 | $71.42 | +6.92% | +26.19% | (19.27%) |
| 2022 | $96.36 | $66.80 | (30.68%) | (18.17%) | (12.51%) |
| 2021 | $62.04 | $96.36 | +55.32% | +28.74% | +26.58% |
| 2020 | $65.06 | $62.04 | (4.64%) | +18.37% | (23.01%) |
| 2019 | $84.65 | $65.06 | (23.14%) | +31.22% | (54.36%) |
| 2018 | $85.42 | $84.65 | (0.90%) | (4.56%) | +3.66% |
| 2017 | $63.39 | $85.42 | +34.75% | +21.70% | +13.05% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
